Titlebook: p53 in the Clinics; Pierre Hainaut,Magali Olivier,Klas G. Wiman Book 2013 Springer Science+Business Media New York 2013 TP53.cancer resear

非实体

可卡

Designing p53 Trials: A Surgical Oncologists View,ement among experts as to how new anticancer drugs should be evaluated before they can be used in standard therapy. However, a corresponding algorithm for the clinical implementation of markers does not exist..Before designing a phase III marker trial one must know whether the marker being tested pr

易弯曲

6Applepolish

被诅咒的人

, Somatic Mutations: Prognostic and Predictive Value in Human Cancers,edictive value of TP53 mutation status in cancer patients. Despite many studies showing a poor prognosis associated with TP53-mutated status, no consensus results have been produced that could support clinical applications. Here, we review these studies, in particular those performed in the context of specific treatment regimen.

definition

sulcus

CULP

Designing p53 Trials: A Surgical Oncologists View,wledge of the underlying scenario is a prerequisite to decide on the optimal marker trial design..We describe a generally applicable algorithm for clinical evaluation of a marker. The algorithm is applied to current knowledge concerning the marker p53.

–DOX

GIDDY